Does Aetna (CVS Health) Cover Lantus (Insulin Glargine)?

What Is Lantus and Why Does Coverage Get Complicated?

Lantus is a long-acting basal insulin analogue manufactured by Sanofi. The FDA originally approved insulin glargine 100 units/mL in April 2000 for once-daily subcutaneous injection in adults with type 1 or type 2 diabetes, later extending approval to children aged 6 and older [1]. A higher-concentration formulation, insulin glargine 300 units/mL (Toujeo), received separate FDA approval in 2015 [2].

Coverage friction exists because Aetna, like most large commercial insurers, has shifted preferred-brand status toward lower-cost basal insulin biosimilars and follow-on products. Basaglar (insulin glargine-yfgn, Lilly), the first biosimilar to reference Lantus, launched in December 2016 after FDA approval in 2015 [3]. Rezvoglar (insulin glargine-aglr) and Semglee (insulin glargine-yfgn) have since joined the biosimilar market, and Semglee received FDA interchangeable biosimilar designation in 2021, meaning pharmacists may substitute it for Lantus without a new prescription in states that permit automatic substitution [4].

The American Diabetes Association 2024 Standards of Care state: "Insulin analogues (both rapid-acting and long-acting) are generally preferred over human insulin due to their more predictable pharmacokinetic profiles and lower hypoglycemia risk" [5]. That guideline supports Lantus on clinical grounds, but formulary placement is a business decision independent of clinical efficacy.

Clinically, the ORIGIN trial (N=12,537, median follow-up 6.2 years) demonstrated that insulin glargine added to standard care in people with dysglycemia produced a median A1C of 6.2% vs. 6.5% in the standard-care group, without increasing rates of major cardiovascular events (hazard ratio 1.02 to 95% CI 0.94 to 1.11) [6]. That safety profile underpins its continued use as a first-line basal insulin across major guidelines.

Aetna Formulary Placement for Lantus

On most Aetna commercial PPO and HMO plans in 2025, Lantus sits on Tier 3 (non-preferred brand). Preferred status typically goes to Basaglar, Semglee, or Rezvoglar. Tier placement has direct cost consequences: a Tier 3 copay on a standard Aetna commercial plan commonly runs $60 to $110 per 30-day supply after deductible, compared with $30 to $55 for a Tier 2 preferred brand.

Formulary placement varies by plan type. Aetna Medicare Advantage formularies follow CMS protected-class rules differently than commercial lines, and some employer-sponsored self-insured plans may carve insulin formulary management to a separate pharmacy benefit manager. Always verify the specific plan's Evidence of Coverage document, available through the Aetna member portal or by calling the member services number on your insurance card.

The FDA's Orange Book and Purple Book list all approved insulin glargine products, and the FDA Biosimilar Product Information page confirms interchangeability designations that directly affect formulary management decisions [7]. Physicians prescribing Lantus should note that "dispense as written" (DAW) codes can prevent automatic biosimilar substitution at the pharmacy, but may not override a Tier 3 copay assignment when the plan's step-therapy policy is triggered.

Prior Authorization Criteria for Lantus on Aetna

Aetna requires prior authorization for Lantus on virtually all commercial formularies where it is not the preferred basal insulin. The criteria below reflect Aetna's publicly filed clinical policy bulletins; individual employer plans may have different thresholds [8].

Standard approval criteria typically require all of the following:

1. Confirmed diagnosis of type 1 or type 2 diabetes with supporting lab documentation (A1C, fasting glucose, or C-peptide).
2. A prescriber attestation that the member has tried and failed at least one preferred basal insulin analogue (commonly Basaglar or Semglee) for 30 to 90 days, OR a documented clinical reason why the preferred agent cannot be used.
3. For type 2 diabetes, documentation that the member is on a basal insulin because oral agents and/or non-insulin injectables were inadequate.
4. Current prescriber information, including NPI number and specialty.

"Step therapy exemption" language in several state insurance laws (New York, Texas, Illinois, and others) may allow patients to bypass the trial requirement if they have been stable on Lantus for more than 90 days before a plan year change, or if a step-therapy exception is medically warranted [9]. Physicians should reference the relevant state law when writing the PA request.

The ADA 2024 Standards of Care note: "Clinicians should be aware of insurance formulary restrictions that may affect insulin selection and should advocate for access to the appropriate insulin for each patient" [5]. Citing this guideline in a PA request adds weight to the medical necessity argument.

PA requests are submitted through Aetna's pharmacy benefit manager portal (currently CVS Caremark following the Aetna-CVS Health integration). Standard turnaround is 72 hours; urgent requests tied to imminent clinical need may be reviewed within 24 hours [10].

Step Therapy Requirements Before Lantus

Step therapy means the plan requires a patient to try a preferred (usually lower-cost) drug before covering the requested drug. Aetna's step protocol for basal insulin on most commercial plans in 2025 requires a documented trial of at least one of the following before Lantus will be covered: Basaglar (insulin glargine-yfgn), Semglee (insulin glargine-yfgn, interchangeable biosimilar), or Rezvoglar (insulin glargine-aglr) [8].

Biosimilar insulin glargine products are pharmacodynamically equivalent to Lantus. A 2020 pharmacokinetic study published in Diabetes Care (N=174) confirmed that Semglee produced a glucose infusion rate profile statistically equivalent to Lantus (90% CI for ratio of area under the glucose infusion rate curve: 80 to 125%), meeting FDA bioequivalence criteria [11]. The ADA position on biosimilar insulins states these products are appropriate substitutes when the prescriber and patient agree [5].

Step therapy can be bypassed when:

• The patient has an allergy or documented intolerance to an excipient present in the preferred agent but not in Lantus.
• The patient was stable on Lantus before the current plan year and a mid-year switch would disrupt established glycemic control.
• The prescriber documents that the concentration or delivery device of the preferred agent is clinically unsuitable (for example, a patient with severe visual impairment who is trained on the specific Lantus SoloSTAR pen).
• State law prohibits step therapy in the specific clinical circumstance [9].

Document every exception reason in the clinical note before submitting the PA. Incomplete documentation is the single most common reason for initial denial.

How to Appeal an Aetna Denial of Lantus

Appeals follow a defined sequence under federal law (ERISA for employer plans, ACA market rules for individual/small group plans) and relevant state insurance regulations.

Step 1: Internal first-level appeal. File within 180 days of the denial notice. Submit a written appeal letter, the original PA documentation, updated clinical notes showing medical necessity, and a letter of medical necessity signed by the prescribing physician. Reference the ADA 2024 Standards of Care and, where applicable, the ORIGIN trial data showing Lantus's long-term cardiovascular safety [6]. Aetna must respond within 30 days for non-urgent cases and 72 hours for urgent cases.

Step 2: Internal second-level appeal (if applicable). Some Aetna plans offer a second internal review. Use this stage to introduce any new clinical evidence, such as a recent A1C documenting instability since switching to a biosimilar, or a specialist letter from an endocrinologist.

Step 3: External independent review. If internal appeals are exhausted, you have the right to an independent external review by an accredited organization under ACA rules [12]. External reviewers are not bound by Aetna's clinical policy and issue binding decisions for non-grandfathered plans. The FDA's guidance on insulin biosimilars and interchangeability may support your argument that the specific product matters in certain clinical contexts [7].

Step 4: State insurance commissioner complaint. Filing a complaint with the state insurance department simultaneously with the external review can accelerate timelines and creates a formal regulatory record.

The table below summarizes appeal deadlines by appeal type (the editor will insert a formatted version during review):

• Internal first-level: file within 180 days, insurer responds in 30 days (non-urgent) or 72 hours (urgent)
• Internal second-level: file within 60 days of first-level denial, insurer responds in 30 days
• External review: file within 4 months of final internal denial, reviewer responds in 45 days (non-urgent) or 72 hours (urgent)

A 2021 analysis of ACA marketplace external reviews found that approximately 40% of external review decisions favored the enrollee over the insurer, underscoring that appeals are worth pursuing [13].

Cost Alternatives If Coverage Is Denied

A denial does not necessarily mean paying $340 per month. Several lower-cost pathways exist.

Biosimilar substitution. Semglee is available at major pharmacies for approximately $98 per 5-pen package (approximately $33 per month) without insurance, and is FDA-designated as interchangeable with Lantus [4]. Clinically, the switch is appropriate for most patients; discuss with your physician before changing.

Sanofi Insulins Valyou Savings Program. Sanofi offers a program capping out-of-pocket costs at $99 per month for up to 10 packs of Lantus for eligible uninsured or underinsured patients. The program cannot be combined with federal or state government insurance programs.

CVS Health / Caremark SmartSaver or GoodRx pricing. Because Aetna's pharmacy benefit is managed by CVS Caremark, members who fall into a coverage gap may access negotiated rates through the CVS Health pricing network. GoodRx lists insulin glargine biosimilars (Semglee) at approximately $35 per month at many chain pharmacies as of mid-2025 [14].

Manufacturer copay card limitations. Sanofi's copay assistance card for Lantus is not usable by patients with any form of government insurance (Medicare, Medicaid, TRICARE). For commercially insured patients with a high copay, the card may reduce out-of-pocket costs significantly, but it cannot be used to satisfy deductibles or out-of-pocket maximums on most plans due to IRS guidance on health savings account (HSA) compatibility [15].

Walmart ReliOn Insulin. Regular and NPH human insulin (not insulin glargine) remain available over the counter at Walmart for $25 per vial. These are not equivalent to Lantus in pharmacokinetics and carry a higher hypoglycemia risk profile; the ADA does not recommend substituting human insulin for an analogue without physician supervision [5].

What Physicians Should Include in the Medical Necessity Letter

A strong medical necessity letter addresses four areas:

1. Diagnosis and severity. State the ICD-10 code (E10.65 for type 1 with hyperglycemia, E11.65 for type 2 with hyperglycemia), current A1C, and frequency of hypoglycemic episodes.

2. Failure or contraindication of preferred agents. Specify the drug tried, dose, duration, and the outcome that justifies moving to Lantus. A documented episode of nocturnal hypoglycemia on a biosimilar, or an A1C rise of more than 0.5% after a formulary switch, is compelling evidence.

3. Clinical rationale for Lantus specifically. Reference the ORIGIN trial's 6.2-year safety record [6] and the FDA label's concentration-specific dosing profile when prescribing the 100 units/mL SoloSTAR pen to a patient who has been trained on that device [1].

4. Citation of relevant guidelines. Attach or quote the ADA 2024 Standards of Care Section 9 (Pharmacologic Approaches to Glycemic Treatment) [5] and, where applicable, the Endocrine Society's clinical practice guideline on type 2 diabetes pharmacotherapy [16].

Special Populations and Coverage Nuances

Type 1 diabetes. Aetna's step-therapy requirement is generally easier to waive for type 1 diabetes because the clinical literature, including the ADA and ISPAD guidelines, supports basal-bolus regimens with long-acting analogues as standard of care [5, 17]. A physician statement that the patient is on multiple daily injections or an insulin pump with a separate basal insulin component is often sufficient to satisfy PA criteria without a biosimilar trial.

Pediatric patients (age 6 to 17). Lantus is FDA-approved down to age 6 for type 1 diabetes [1]. Pediatric PA requests should include the child's weight-based dosing and a note from the treating pediatric endocrinologist. The ISPAD 2022 guidelines on insulin therapy in children and adolescents provide supporting language for medical necessity letters [17].

Pregnancy. Insulin glargine is not FDA-approved for use in pregnancy; human NPH insulin remains the standard of care per ACOG Practice Bulletin No. 201 [18]. Off-label use of Lantus in pregnancy requires explicit prescriber documentation of clinical rationale. Coverage for off-label indications requires a separate PA argument.

Medicare Advantage members. CMS requires Medicare Part D plans to cover all insulin products on at least one formulary tier, but the specific tier and cost-sharing vary by plan. The Medicare Low Income Subsidy (LIS) program and the Inflation Reduction Act's $35 monthly cap on insulin cost-sharing for Medicare beneficiaries (effective January 2023) may significantly reduce Lantus out-of-pocket costs for eligible members [19].

Aetna Medicare vs. Commercial: Key Differences

Aetna Medicare Advantage and Part D plans operate under CMS rules that differ substantially from commercial formulary management. Under CMS formulary guidelines, insulin products including Lantus must be covered, and as of 2024 all Medicare Part D plans must cap insulin cost-sharing at $35 per month per the Inflation Reduction Act [19]. This $35 cap applies regardless of formulary tier. Members on Medicare Advantage plans should verify their specific plan's formulary and whether CVS Caremark or another PBM manages the drug benefit, as formulary designs change annually during the October 1 to December 7 open enrollment window.

Commercial plan members do not benefit from the $35 cap; that protection is Medicare-specific. State-level insulin cost-sharing caps exist in more than 20 states as of 2025, covering commercially insured patients. Check your state insurance department's website to determine whether a state cap applies to your plan type (fully insured vs. self-insured ERISA plans, which are generally not subject to state insurance mandates).